|
Volumn 28, Issue 3 SUPPL. 59, 2010, Pages
|
Biologic agents in rheumatology: Act II
|
Author keywords
Certolizumab pegol; Rheumatoid arthritis; TNF inhibitors
|
Indexed keywords
CORTICOSTEROID;
METHOTREXATE;
TUMOR NECROSIS FACTOR INHIBITOR;
CERTOLIZUMAB PEGOL;
IMMUNOGLOBULIN F(AB) FRAGMENT;
MACROGOL DERIVATIVE;
TUMOR NECROSIS FACTOR ALPHA;
ACT;
CLINICAL ASSESSMENT;
CLINICAL PRACTICE;
COST EFFECTIVENESS ANALYSIS;
DRUG SAFETY;
DRUG TOLERABILITY;
EDITORIAL;
HUMAN;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
REMISSION;
RHEUMATOID ARTHRITIS;
RHEUMATOLOGY;
SPONDYLITIS;
DRUG ANTAGONISM;
ARTHRITIS, RHEUMATOID;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
POLYETHYLENE GLYCOLS;
RHEUMATOLOGY;
TUMOR NECROSIS FACTOR-ALPHA;
|
EID: 77956411179
PISSN: 0392856X
EISSN: 1593098X
Source Type: Journal
DOI: None Document Type: Editorial |
Times cited : (1)
|
References (10)
|